Novo Nordisk has recently faced diminished sales for its GLP-1 diabetes and obesity drugs like Ozempic and Wegovy, experiencing a slowdown from 21% to 8% in sales growth during the first half of the year. The drugmaker has encountered increased competition from Eli Lilly's Mounjaro and faced market pressure due to cheaper generic versions. As a result, the company aims to cut costs and focus on commercial execution, predicting future sales growth to be between 8% and 14% by 2025. Novo Nordisk's leadership is confident in capitalizing on the global obesity treatment market, continuing to invest despite challenges.
"Novo Nordisk has lost $95bn in market value since cutting its full-year sales forecast last week as competition intensifies and US tariffs loom."
"Sales growth for medications like Ozempic was only 8% in the first half of the year, a drastic decline from the previous year's 21% increase."
"Novo Nordisk aims to sharpen commercial execution and improve cost efficiencies while continuing to invest in future growth, expecting sales growth of 8% to 14% for 2025."
"Currently, over 1 billion people live with obesity globally, with significant growth opportunities identified under the leadership of Mike Doustdar."
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]